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Context: The detection of low- level persistent or relapsed B- cell neoplasms, particu-
larly post- therapy, can be challenging, often requiring multiple testing modalities.
Objective: Here we investigate the utility of CD19- based selection of neoplastic B- 
cells (CD19S) as an enrichment strategy to improve the detection rate of cytogenetic 
abnormalities in post- therapy samples of B- cell neoplasms, especially those with low- 
level disease.
Design: In a cohort largely comprised of post- therapy B- ALL and CLL samples, we 
performed fluorescence in situ hybridization (FISH) analysis on CD19- selected cells 
(CD19S FISH) in 128 specimens from 88 patients, and on non- selected cells (NS 
FISH) in a subset of cases. The FISH findings were compared with the concurrent 
flow cytometry (FC) results in all samples and molecular analysis in a subset.
Results: CD19S FISH was able to detect cytogenetic aberrations in 86.0% of post- 
therapy samples with evidence of disease as determined by routine or MRD FC, com-
pared to 59.1% of samples by NS FISH. CD19S FISH detected significantly higher 
percentages of positive cells compared to NS FISH (p < 0.001). Importantly, CD19S 
FISH enabled the detection of emergent subclones (clonal evolution) associated with 
poor prognosis.
Conclusions: CD19S FISH can be useful in daily diagnostic practice. Compared to 
NS FISH, CD19S FISH is quantitatively and qualitatively superior for the detection 
of cytogenetic aberrations in B- cell neoplasms, which are important for risk stratifi-
cation and optimal management of patients with B- cell neoplasms, especially in the 
relapsed setting. Although CD19S FISH has a diagnostic sensitivity inferior to that of 
MRD FC, the sensitivity of this modality is comparable to routine FC for the evalu-
ation of low- level disease in the post- therapy setting. Moreover, CD19S samples are 
invaluable for additional molecular and genetic analyses.
K E Y W O R D S
B- cell, CD19- selection, cytogenetics, FISH, flow cytometry, karyotype, leukemia, lymphoma, 
measurable residual disease, minimal disease, neoplasm, post- therapy
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1 |  INTRODUCTION
Detection of cytogenetic or molecular aberrations plays an 
integral role in the diagnosis, classification, and manage-
ment of B- cell neoplasms.1 Recurrent genetic aberrations 
are also important for risk stratification of patients with 
B- cell neoplasms, particularly in chronic lymphocytic leu-
kemia/small lymphocytic lymphoma (CLL/SLL)2 and B 
lymphoblastic leukemia/lymphoma (B- ALL).3 However, 
the ability to detect such aberrations in peripheral blood, 
bone marrow, and other samples with low- level disease 
can be challenging, particularly post- therapy, to assess 
for measurable residual disease (MRD) or early relapse. 
Currently, flow cytometry (FC) is the standard method 
for detecting MRD in B- ALL, plasma cell neoplasms, and 
acute myeloid leukemia. Another current method used in 
the detection of B- ALL MRD is polymerase chain reaction 
(PCR) analysis.4
A number of methods have been devised to separate and en-
rich neoplastic cells from complex cellular mixtures that target 
cell and cancer- specific surface antigens.5 Of these, magnetic- 
activated cell sorting (MACS) has become the standard modal-
ity due to its affordability, ease of use, high- throughput, and high 
purity for isolating different cell types through the use of single 
or multiple antibody- coated magnetic beads.6,7 Sorted cells can 
then be interrogated by cytogenetic or molecular techniques, 
such as interphase fluorescence in situ hybridization (FISH) 
and next- generation sequencing. Utilization of CD138- positive 
MACS coupled with interphase FISH is currently widely used 
for the detection of recurrent cytogenetic aberrations in plasma 
cell neoplasms.8,9 A few prior studies have documented the use 
of CD19- positive MACS to evaluate B- cell neoplasms, mostly 
CLL/SLL, in post- therapy settings,10,11 for determining prog-
nostic markers,12 and characterizing the mutational landscapes 
of B- cell neoplasms.13,14 Sporadic reports have described the 
clinical application of CD19 selection coupled with interphase 
FISH analysis for the evaluation of CLL/SLL.15,16 However, 
to the best of our knowledge, no previously published studies 
have systematically and comprehensively evaluated the utility 
of FISH analysis on CD19- selected cells in the detection of B- 
cell neoplasms in routine diagnostic practice.
The aim of the present study was to compare the findings 
of interphase FISH analysis performed on CD19- selected cells 
(CD19S FISH) with those of FISH performed on non- selected 
cells (NS FISH), and also compare the results with concurrent 
FC analysis (routine and MRD FC) and molecular polymerase 
chain reaction (PCR) analysis in various types of mature and im-
mature CD19- positive B- cell neoplasms. We show that CD19S 
FISH is quantitatively and qualitatively superior to NS FISH 
for detecting cytogenetic aberrations as well as in identifying 
emerging subclones, especially post- therapy. Furthermore, the 
sensitivity of CD19S FISH is comparable to routine FC for 
monitoring low- level disease persistence or relapse.
2 |  MATERIALS AND METHODS
2.1 | Case selection
We retrospectively analyzed consecutive pediatric and adult 
bone marrow aspirate and peripheral blood samples involved 
by B- cell neoplasms over a period of 23 months (June 2018- 
April 2020). The criteria for case selection included: i) ma-
ture and immature B- cell neoplasms, with either a previously 
established diagnosis at our institution or newly determined 
from diagnostic/untreated samples, ii) known chromosomal 
aberrations detectable by FISH, and iii) concomitant evalu-
ation of samples by either routine or MRD FC. Pathological 
diagnoses and results of all routine morphology and ancil-
lary studies were retrieved from our departmental database. 
Disease detection by FC analysis was considered the “gold- 
standard” for the purpose of this study. The study was per-
formed in accordance with the principles of the Declaration 
of Helsinki and a protocol approved by the Institutional 
Review Board of Columbia University Human Research 
Protection Office.
2.2 | Flow cytometry
Routine multi- color FC or B- ALL MRD FC analysis, con-
ducted on a BD FACSCanto II cell analyzer (Becton, 
Key points
1. A systematic comparison of CD19S FISH versus NS FISH analysis establishes 
superiority (qualitative and quantitative) of the former modality in detecting post- 
therapy persistence or relapse of B- cell neoplasms.
2. CD19S FISH can complement flow cytometric evaluation for the detection of low- 
level involvement in B- cell neoplasms and particularly in the detection of post- 
therapy recurrent/emerging small subclones.
3. Flow cytometry detection of <1% positive cells was predictive of a “negative” non- 
selected FISH outcome; further suggesting the benefit of FISH analysis on CD19- 
selected cells post- therapy.
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Dickinson and Company, Franklin Lakes, NJ), was per-
formed on bone marrow aspirate and peripheral blood 
samples to evaluate B- cell neoplasms. All samples were pro-
cessed as previously described.17 Four- and eight- color FC 
antibody panels were used, including B- cell (CD19, CD20, 
CD45, surface κ, surface λ, CD10, CD5, CD43, CD103, 
CD23, CD38, FMC7, CD11c, CD30, CD34, CD52, IgM, 
IgD, cytoplasmic IgM, cytoplasmic CD79a, and TdT), and 
plasma cell (CD138, CD38, CD117, CD56, CD27, CD28, 
CD45, CD19, CD20, cytoplasmic κ, and cytoplasmic λ) pan-
els. The B- ALL MRD panel comprised CD20, CD10, CD38, 
CD19, CD58, CD45, CD9, CD13&33, CD34, CD3 and CD71 
markers. All antibodies were obtained from BD Biosciences 
(Franklin Lakes, NJ). Data collection and analysis were per-
formed using BD FACSDiva software (BD Bioscience, San 
Jose, CA) and FCS Express version 5 (DeNovo Software, 
Pasadena, CA), respectively. The accepted limit of detection 
for routine FC in our laboratory was 0.1% and for B- ALL 
MRD FC was 1/10,000 events. The average number of cells 
per tube analyzed by routine FC in bone marrow specimens 
in this study was approximately 41,000, and in peripheral 
blood specimens was approximately 16,000, while the aver-
age number of events collected by MRD was approximately 
1,400,000.
2.3 | Magnetic- bead based Cell selection
CD19 magnetic- bead- selection and enrichment of cells 
of interest was performed with the RoboSep- S instrument 
(STEMCELL Technologies, Vancouver, Canada) accord-
ing to the manufacturer's protocol. Briefly, the sample was 
diluted 5- fold using RoboSep dilution buffer (STEMCELL 
Technologies, Vancouver, Canada), mixed gently, and spun 
at 300  g for 10  minutes, followed by the aspiration of the 
supernatant. The sample was then diluted to the original 
volume with RoboSep buffer and mixed well. If required, 
the sample was filtered through a pre- wetted 70 µm strainer 
(Fisher Scientific, Waltham, MA) to remove bone frag-
ments and cell aggregates or debris. The sample was diluted 
1:1 in EasySep RBC buffer (STEMCELL Technologies, 
Vancouver, Canada), transferred to a 14  ml centrifuge 
tube, and processed on the RoboSep- S instrument using 
the RoboSep HLA Chim WB CD19 Positive Selection Kit 
(STEMCELL Technologies, Vancouver, Canada). In- house 
magnetic- bead selection achieved CD19+ cell purities within 
the stated range of the manufacturer (94.3%– 99.6%).
2.4 | Cytogenetic/FISH analysis
FISH analysis was performed on CD19S and NS cells using 
standard protocols. Briefly, CD19S and NS cells were 
subjected to hypotonic treatment for 10 minutes, followed by 
fixing the cells with fresh 3:1 methanol- acetic acid fixative 
three times, and preparing the slides by the air- dry method. 
The yield of cells after CD19- selection varied depending on 
the extent of disease and the amount of sample available for 
selection. Whenever possible, at least 200 interphase cells 
were scored for each probe. In samples with low cellular 
recovery, a minimum of 100 cells were required to be in-
cluded in the study. The panel of probes (Abbott Molecular, 
Des Plaines, IL or Cytocell, Tarrytown, NY) for detecting 
specific chromosomal aberrations in B- ALL, CLL/SLL, and 
other B- cell neoplasms, and their respective normal variation 
cut- offs are listed in Table 1.
2.5 | Molecular analysis
Immunoglobulin heavy chain (IGH) gene rearrangement 
(IGH PCR): Multiplexed fluorescent PCR amplifica-
tion was performed on an ABI 3500xL genetic analyzer 
(Thermo Fisher Scientific, Waltham, MA), using six VH- 
FR1 primers (tube A), seven VH- FR2 primers (tube B), 
seven VH- FR3 primers (tube C), six DH primers (tube 
D) and one DH7 primer (tube E), all with a consensus re-
verse JH primer (IdentiClone IGH Gene Clonality Assay, 
Invivoscribe Inc., San Diego, CA), followed by high- 
resolution capillary electrophoresis and fragment analysis. 
The detection limit varied from 1 to 10% depending on the 
specific rearrangement.
BCR- ABL1 RT- PCR: Extracted RNA was subjected to 
quantitative reverse transcription real- time PCR to simultane-
ously measure the quantity of the primary BCR- ABL fusion 
transcripts b2a2, b3a2, and e1a2, using the Asuragen BCR/
ABL1 Quant Assay (Asuragen, Austin, TX). Simultaneous 
PCR amplification of the ABL1 gene was performed as a 
control for sample RNA quality and as a reference for relative 
quantification.
2.6 | Statistical analysis
Comparison of means and odds ratios were analyzed with 
MedCalc for Windows, version 19.2.0 (MedCalc Software, 
Ostend, Belgium).
3 |  RESULTS
3.1 | Overall cohort characteristics
CD19S FISH was performed in a cohort of 128 samples 
from 88 patients over the study period. The male to female 
ratio was 3.7:1 and the median age was 65  years (range: 
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2– 89 years). The samples were derived from bone marrow 
aspirates (85.2%) or peripheral blood (14.8%). The cohort 
largely comprised B- ALL (39.8%, 51/128) and CLL/SLL 
(39.8%, 51/128) samples. Samples of a variety of other B- 
cell neoplasms (20.3%, 26/128) accounted for the remainder 
(Table 1). Twenty- five samples were obtained from untreated 
patients (Table 1), over half of which represented CLL/SLL 
(13/25). The remaining one hundred and three samples were 
obtained post- therapy to determine disease status (including 
all B- ALL samples).
3.2 | Diagnostic versus post- therapy sample 
characteristics
Routine FC detected disease in the majority of untreated (di-
agnostic) samples (84.0%, 21/25), while only 48.5% (50/103) 
of post- therapy samples had disease detectable by FC (routine 
or MRD; Figure 1). CD19S FISH detected disease in 76.0% 
(19/25) of untreated samples, including one unique case where 
CD19S FISH detected disease (FL, 4.8% cells were positive 
for IGH/BCL2 translocation), while both NS FISH and routine 
T A B L E  1  Summary of B- cell neoplasms and FISH probes
Diagnosis† Cases (PT/UD)‡ FISH Probes tested; chromosomal target Normal variation§ 





TEL/AML1 (ETV6/RUNX1); 12p13.2/21q22 1%
CEP4/CEP10/CEP17; (hyperdiploidy panel); 4p11- q11/10p11- q11/17p11.1- q11.1 2%
XY; Xp11- q11/Yq12 1%
TCF3/PBX1 dual fusion; 19p13.3/1q23 1%
MLL break apart (KMT2A); 11q23 1%






















IGH break apart See above
MALT1 break apart; 18q21 2%
BCL6 break apart; 3q27 1%
MCL 9 (8/1) IGH/CCND1 dual fusion; 14q32/11q13 1%
D13S319/13q34/CEP12 See above
FL 5 (3/2) IGH/BCL2; 14q32/18q21 1%
LPL 4 (1/3) D13S319/13q34/CEP12 See above
B- PLL 1 (0/1) TP53/CEP17 See above
PTLD 1 (0/1) IGH/MYC/CEP8;
14q32/8q24/8p11.1- q11.1
1%
†B- ALL, B- lymphoblastic leukemia/lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL/SMZL, marginal zone lymphoma/
splenic marginal zone lymphoma; MCL, mantle cell lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; PTLD, post- transplant 
lymphoproliferative disorder; B- PLL, B- cell prolymphocytic leukemia. 
‡Number of cases including post- therapy follow up/relapse (PT), and untreated disease (UD) samples. 
§Percentage range of normal variation (95% confidence interval) cut- offs in our laboratory. 
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FC did not (Figure 1, green column and Table S1, sample 1). 
IGH PCR analysis also detected a clonal IGH rearrangement 
in sample 1 (see below), further supporting the presence of dis-
ease in this sample (Table S1). Unfortunately, few untreated 
samples were tested by NS FISH (5/25 samples), precluding 
an accurate comparison of the ability of both FISH modalities 
to detect disease in untreated samples (Figure 1).
A variety of chemotherapeutic drug regimens were used 
to treat the different B- cell neoplasms, which are listed in 
Table  S1. Rituximab, a monoclonal antibody that targets 
CD20 antigen, was the most commonly used drug (44/103 
samples; Table  S1). Post- Rituximab therapy samples that 
were positive for disease demonstrated no apparent decrease 
in the sensitivity of CD19S FISH (90.9%; 20/22 samples) 
compared to that in alternative therapy samples (82.1%; 
23/28). The median duration elapsed after Rituximab treat-
ment prior to positive disease sample collection was 6 months 
(range of 0.25 to 108 months elapsed), while the same statis-
tic for negative disease samples was 7.25 months (range 0.25 
to 125 months elapsed). Treatments directly targeting CD19 
antigen (Blinatumomab or chimeric antigen receptor T- cell 
therapy (CAR- T)) were used in 12 cases (10 B- ALL and two 
follicular lymphoma cases; Table S1). Specifically, 8 samples 
of B- ALL were post single Blinatumomab therapy and seri-
ally derived from the same patient, of which 5 samples were 
positive for refractory disease by both FC (bright CD19 anti-
gen) and CD19S FISH, including the first sample in the series 
(8 days post- application). While the other 4 samples, compris-
ing two samples of B- ALL and two samples of FL, were post- 
CAR- T and negative for disease by both FC and CD19S FISH.
3.3 | Concordance of molecular testing with 
FC and CD19S FISH
IGH PCR was performed in 21.9% (28/128) of the samples and 
BCR- ABL1 RT- PCR in four samples. BCR- ABL1 RT- PCR 
analyses were in complete agreement with FC and CD19S FISH 
results. IGH PCR analyses were overall in good agreement with 
results of FC and CD19S FISH, but in 14.3% (4/28) and 10.7% 
F I G U R E  1  Relative proportion of cases assayed by the different testing modalities. Pie charts represent the relative proportion of cases 
assayed by FC (large chart includes both routine and MRD FC; small chart includes MRD FC only) and CD19S FISH, with or without NS FISH 
(“exploded” pie segments represent cohorts with NS FISH testing). Data are derived from the inset table and the corresponding ratios for segments 
in the large chart are given in parentheses. Positive (+) or negative (- ) detection by the type of testing modality is denoted. White and light gray 
segments represent the proportion of cases without detectable disease. Black and dark gray segments represent the proportion of positive cases 
detected by FC and CD19S FISH, with or without NS FISH testing, respectively. Gold segments represent the proportion of cases positive by 
CD19S FISH and negative by NS FISH. Red and brown segments represent the proportion of cases positive by FC but negative by CD19S FISH, 
with or without NS FISH testing, respectively
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(3/28) of samples, IGH PCR results were discrepant from FC 
and CD19S FISH results, respectively. Notably, two molecular 
tests detected clonal peaks when FC was negative (Table S1; 
cells highlighted in gray): Sample 1 was concordant with 
CD19S FISH and was accordingly designated as a “positive” 
sample, whereas, sample 115 was discordant with both CD19S 
FISH and FC results and was designated a “negative” sample.
3.4 | Comparison of CD19S FISH with NS 
FISH in post- therapy samples
CD19S FISH was positive in 86.0% of all post- therapy sam-
ples that had FC detectable disease (43/50; Figure 1), with 
the percent positive cells ranging from 2 to 99% (Table S1). 
NS FISH was performed in 44.0% of all positive samples 
(22/50) and detected disease in 59.1% (13/22; Figure 1), with 
percent positive cells ranging from 1.5 to 51.5% (Table S1). 
NS FISH did not detect disease in any samples negative by 
either FC or CD19S FISH.
Twenty- two post- therapy “positive” samples (compris-
ing 25 chromosome aberrations) had data on both CD19S 
FISH and NS FISH, allowing direct comparison of these 
different FISH technique modalities in the detection of chro-
mosome aberrations (Table  2). The average percentage of 
positive cells detected by NS FISH and by CD19S FISH was 
10.10 ± 15.65% and 42.24 ± 38.23%, respectively (Table 2). 
CD19S FISH consistently detected a higher percentage of 
T A B L E  2  Summary of chromosomal aberrations in treated samples detected by all testing modalities (NS FISH, CD19S FISH, and FC) 
expressed as the percentage of cells
Diagnosis† Chromosomal aberration NS FISH CD19S FISH FC FC mean ±SD
B- ALL BCR/ABL 0 25 0.1 0.30 ± 0.70
‡ B- ALL Monosomy 7 0 12.1 0.2
‡ B- ALL del(7q) 0 9 0.2
B- ALL Hyperdiploidy 0 2 ¶ 0.08
B- ALL Hyperdiploidy 0 0 ¶ 0.039
B- ALL Hyperdiploidy 0 0 ¶ 0.02
B- ALL Hyperdiploidy 0 3.3 ¶ 0.016
B- ALL 3 copies PBX1 0 15.5 ¶ 0.012
CLL/SLL del(13q14) 0 7 0.1
CLL/SLL PRDM1 0 6.7
MCL IGH/CCND1 0 6.5 2.4
‡ B- ALL BCR/ABL 1.6 81.5 0.2 18.15 ± 17.83
B- ALL BCR/ABL 51.5 97 30
B- ALL BCR/ABL 21.5 99 ¶ 14.749
§ CLL/SLL del(13q14) 6.5 29.5 19
CLL/SLL del(13q14) 4 91 5
§ CLL/SLL Trisomy 12 /del(13q14) 21 69 19
CLL/SLL Trisomy 12 39.5 81 4.9
CLL/SLL Trisomy 12 2.3 33.6 5
CLL/SLL TP53 del 10 17 65
CLL/SLL ATM del 9.5 98.5 21.5
CLL/SLL ATM del 47 85 38.5
CLL/SLL ATM del 11 84 25
MCL IGH/CCND1 1.5 4.3 0.26
MZL del(7q) 5.5 14 6
Mean ± SD 10.10 ± 15.65 42.24 ± 38.23
†B- ALL, B- lymphoblastic leukemia/lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; MZL, marginal zone lymphoma; MCL, 
mantle cell lymphoma; FL, follicular lymphoma. Chromosomal aberrations detected by CD19S FISH and/or FC, but undetected by NS FISH are highlighted in gray. 
‡Chromosomal aberrations in the same B- ALL sample. 
§Chromosomal aberrations in the same CLL/SLL sample. 
¶Disease detected by MRD FC. 
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positive cells than NS FISH (Figure 2), and a comparison of 
means found a significantly increased rate of the detection of 
chromosomal aberrations by CD19S FISH compared to NS 
FISH (p < 0.001). Furthermore, within the subset of positive 
samples tested by both FISH modalities, 72.7% (8/11) of B- 
ALL, 18.2% (2/11) of CLL/SLL, and 33.3% (1/3) of other 
B- cell neoplasms had chromosomal aberrations that were 
uniquely detected by CD19S FISH (Table 2 and Figure 2). 
NS FISH did not effectively detect disease in B- ALL sam-
ples with post- therapy minimal disease (2/11 chromosome 
aberrations detected), but yielded informative results in other 
B- cell neoplasms, particularly CLL/SLL (9/11 chromosome 
aberrations; Table 2).
3.5 | Detection of rare subclones by 
CD19S FISH
After careful review of morphology (and in one case, after 
an additional selected FISH panel), no chromosomal aber-
ration in this study was attributed to an underlying myeloid 
neoplastic clone. In the entire cohort (untreated and post- 
therapy samples), 9 CLL/SLL, 5 B- ALL (same patient), one 
SMZL, and one LPL sample had multiple recurrent chromo-
somal aberrations detectable by FISH, all other FISH posi-
tive samples had only one detectable aberration (Table S1). 
In these samples, CD19S FISH not only detected low- level 
disease, but also detected persistent or emerging new sub-
clonal abnormalities. For example, a B- ALL sample with a 
BCR- ABL t(9;22) stem- line clone (detected by both NS and 
CD19S FISH), also contained rare (previously detected) sub-
clones with monosomy 7 and deletion 7q, that in this instance 
were detected only by CD19S FISH (Table 2 and Table S1, 
Sample 5). Examples of emerging subclones in CLL/SLL 
samples uniquely detected only by CD19S FISH include: 
i) two subclones including one with ATM and TP53 dele-
tions and one with MYC rearrangement, both likely derived 
from a stem- line with an ATM deletion (Table S1, Sample 
128), ii) a subclone with ATM deletion from a trisomy 12 
stem- line (Table S1, Sample 45), and iii) two subclones con-
taining heterozygous deletion of 13q14, and 13q14 deletion 
plus trisomy 12, derived from a stem- line with deletion TP53 
(Table S1, Sample 77).
3.6 | Comparison of FC and FISH in post- 
therapy samples
Flow cytometry, either routine or B- ALL MRD FC, was per-
formed in the entire post- therapy cohort and detected disease 
in 50 samples (Figure 1). Seven samples were positive for 
disease by FC (including four MRD flow samples), but nega-
tive by FISH (Figure 1). As stated earlier, NS FISH did not 
detect disease in any sample deemed negative by either FC or 
CD19S FISH. In post- therapy samples that were positive by 
NS FISH, the average percentage of positive cells detected 
by FC was significantly higher compared to samples deemed 
negative by NS FISH (18.15  ±  17.83% vs. 0.30  ±  0.70%, 
p < 0.001), (Table 2). By extrapolation, this finding predicts 
that an FC positive cell detection of <1% will likely have a 
“negative” NS FISH outcome. Whereas, CD19S FISH de-
tected disease in 81.8% of the negative NS samples (9/11; 
Table 2).
When MRD FC samples were excluded from the post- 
therapy cohort, routine FC, CD19S FISH, and NS FISH 
sensitivities in detecting disease were 100 (40/40), 92.5 
(37/40), and 75.0% (12/16), respectively. Thus, the odds ratio 
of CD19S FISH having a different outcome to routine FC 
F I G U R E  2  Comparison of FISH 
modalities. Percentage positive B- ALL 
(A) and non- Hodgkin lymphoma (B) cells as 
detected by NS and CD19S FISH. Specific 
chromosomal abnormalities are indicated by 
colored bars
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was 0.132 (95% CI 0.007– 2.647, p  =  0.186), implying no 
significant difference in the sensitivity of these two meth-
ods. Whereas, the odds ratio of NS FISH having a different 
outcome to routine FC was 0.034 (95% CI 0.002– 0.682, 
p  =  0.027), signifying a statistically inferior sensitivity to 
routine FC in detecting disease.
3.7 | Comparison of B- ALL MRD FC and 
FISH in post- therapy samples
A large proportion of B- ALL samples was analyzed by MRD 
FC (26/51) and the majority were negative for disease (16/26, 
61.5%; Figure 1). FISH analysis did not detect disease in any 
MRD FC negative sample. NS FISH was performed in 6 of 
the 10 positive samples, but detected disease in only one 
sample (sensitivity of 16.7%; Figure  1), whereas CD19S 
FISH detected disease in 6 of 10 samples (sensitivity of 60%; 
Figure 1). Although the number of positive MRD FC cases 
in our cohort is small (n = 10), CD19S FISH, although infe-
rior to MRD- FC, was again notably superior to NS FISH in 
detecting disease.
4 |  DISCUSSION
Prior studies have not systematically evaluated the diag-
nostic utility and applications of CD19S FISH in the detec-
tion of B- cell neoplasms, particularly in comparison to NS 
FISH with concurrent standard FC studies. In this study, 
we demonstrate the advantages of CD19- selection in de-
tecting cytogenetic aberrations in post- therapy samples of 
immature and mature B- cell neoplasms. CD19S FISH sig-
nificantly improved disease detection both quantitatively 
and qualitatively when compared to NS FISH and showed 
high sensitivity in disease detection statistically compara-
ble to routine FC.
Our cohort was predominantly comprised of bone marrow 
aspirate samples obtained after therapy to determine disease 
status. Although the majority of samples were from B- ALL 
and CLL/SLL patients, samples from patients with other 
types of B- cell neoplasms were also represented. CD19S 
FISH proved to be advantageous over NS FISH in B- ALL 
where most of the post- therapy samples had a low disease 
burden (Figure 2). Conversely, many CLL/SLL samples were 
typically derived from untreated disease and contained nu-
merous neoplastic cells, which were detectable by NS FISH 
in a high proportion of samples, making CD19S FISH selec-
tion less advantageous. However, within the subset of positive 
samples tested by both FISH modalities, a number of chro-
mosomal aberrations and persistent/emerging rare subclones 
were uniquely detected only by CD19S FISH, while NS FISH 
did not detect disease in any CD19S FISH negative samples.
Analysis of the effect of direct CD19- targeted therapies, 
which have the potential to down- regulate CD19 surface an-
tigen expression and thereby interfere with B- cell selection 
and enrichment, was hindered by the small number of cases 
and largely inconclusive. The few post- CAR- T therapy sam-
ples were negative for disease by both CD19S FISH and FC, 
while Blinatumomab was applied once to a single patient 
and the post- therapy samples had identical CD19S FISH and 
FC results. Interestingly, there are reports in the literature of 
concurrent down- regulation or loss of CD19 surface anti-
gen by monocyte- mediated trogocytosis or “shaving” during 
Rituximab therapy.18 However, in our cohort, we found no 
evidence of decreased CD19S FISH sensitivity in the pres-
ence of this drug, even after the consideration of the du-
ration of time elapsed from therapy application to sample 
collection.
On comparing the mean percent positive cells detected 
by standard FC of corresponding “negative” and positive 
NS FISH studies, statistically significant differences were 
noted. An FC detection level of <1% percent positive cells 
was highly predictive of a “negative” NS FISH result and 
such samples would potentially benefit from CD19S FISH. 
One caveat to this recommendation is that CD19S FISH does 
not reflect the actual disease burden of neoplastic B- cells in 
a sample since these cells are sorted and enriched, and re-
moved from the background cellular admixture. However, in 
conjunction with FC evaluation, CD19S FISH can provide 
useful information regarding the presence of residual or re-
lapsed disease.
In general, interphase FISH evaluation of low- level dis-
ease is limited by the probes available for disease detection 
and since all FISH probes have normal ranges of variation 
(ranging from 1 to 4% in our study) that can significantly af-
fect the lower limit of disease detection. However, this is mit-
igated when enriching for the cells of interest. Accordingly, 
CD19S FISH demonstrated statistically comparable sensitiv-
ity to routine FC in our study, and in one instance CD19S 
FISH detected disease in an untreated sample (supported 
by molecular PCR analysis) when routine FC was nega-
tive. However, CD19S FISH had a notably inferior sensitiv-
ity to MRD FC for B- ALL. This finding is in keeping with 
MRD FC as the current analytic gold standard for the de-
tection of minimal measurable disease for B- ALL19 and also 
plasma cell myeloma.20 Aside from the exquisite sensitivity 
(1/10,000 events in our laboratory), MRD FC concentrates 
cells of interest by the gating strategy, retaining background 
cells, and thereby can inform of the percentage of neoplastic 
cells in the whole sample. Other highly sensitive techniques 
that are commercially available for B cell MRD detection 
include next- generation sequencing (NGS), which assesses 
clone- associated IGH rearrangements and is considered 
to be an order of magnitude more sensitive than FC.21,22 
Drawbacks of NGS MRD include its considerably longer 
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result turn- around- time, its relative expense, and its inability 
to detect evolving chromosomal aberrations. More investiga-
tive/experimental techniques such as “Immuno- flowFISH,” 
which directly couples FC with FISH, may supersede exist-
ing techniques but are not currently available in daily hema-
topathology practice.23
While CD19S FISH has inferior sensitivity to MRD FC 
and is only a semi- quantitative technique, it can complement 
FC in disease detection and contribute additional cyto genetic 
information important for risk stratification and disease man-
agement. Many examples of rare recurrent/persistent sub-
clones or newly emerging subclones were detected in the 
present study by CD19S FISH alone. Subclones often arise 
under therapy selection pressure and invariably are associ-
ated with worse prognosis.24 The detection of rare emerging 
subclones reveals a qualitative advantage that CD19S FISH 
has over NS FISH and even standard FC. Moreover, CD19S 
samples are enriched with a relatively pure population of 
neoplastic B- cells making them invaluable for additional mo-
lecular and genetic analyses.
Our study has some limitations. NS FISH was not per-
formed in all cases, limiting the statistical power of compari-
sons between the two FISH modalities. Apart from CLL/SLL 
and B- ALL samples, only a limited number of other types of 
B- cell neoplasms were assessed, which precludes assessing 
the utility of CD19S FISH in such cases.
Despite these limitations, our study serves as proof- of- 
principle of the utility and advantages of interphase FISH 
analysis performed on CD19- selected cells over non- selected 
cells for the detection of recurrent cytogenetic aberrations in 
B- cell neoplasms in the post- therapy setting. In addition, the 
study shows that this FISH analysis modality appears unaf-
fected by prior Rituximab treatment and complements and 
has sensitivity comparable to routine FC immunophenotypic 
analysis. Future studies with larger cohorts and a greater vari-
ety of B- cell neoplasms are clearly warranted to further delin-
eate the role of CD19S FISH in the diagnosis and follow- up 
of B- cell neoplasms.
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